Last reviewed · How we verify
Commercially-available Aspirin
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation. Used for Acute myocardial infarction, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.
At a glance
| Generic name | Commercially-available Aspirin |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Pain management; Immunology |
| Phase | Phase 3 |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of prostaglandins (which mediate inflammation and pain) and thromboxane A2 (which promotes platelet clumping). The antiplatelet effect is particularly durable because aspirin irreversibly modifies platelet COX-1, and platelets cannot synthesize new enzyme.
Approved indications
- Acute myocardial infarction
- Ischemic stroke prevention
- Transient ischemic attack (TIA) prevention
- Coronary artery disease
- Mild to moderate pain
- Fever
- Rheumatoid arthritis and other inflammatory conditions
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Hemorrhagic stroke (at higher doses)
- Allergic reactions (including bronchospasm in aspirin-sensitive patients)
- Renal impairment (chronic use)
Key clinical trials
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation (PHASE4)
- Acamprosate and Methazolamide for Essential Tremor (PHASE2)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold (PHASE4)
- STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial (NA)
- To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease. (NA)
- Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Commercially-available Aspirin CI brief — competitive landscape report
- Commercially-available Aspirin updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI